Edwards Lifesciences Price to Free Cash Flow Ratio 2010-2022 | EW
Historical price to free cash flow ratio values for Edwards Lifesciences (EW) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Edwards Lifesciences Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-01-27 |
78.14 |
|
46.86 |
| 2022-09-30 |
82.63 |
$1.67 |
49.55 |
| 2022-06-30 |
95.09 |
$2.01 |
47.37 |
| 2022-03-31 |
117.72 |
$2.27 |
51.85 |
| 2021-12-31 |
129.55 |
$2.23 |
58.15 |
| 2021-09-30 |
113.21 |
$2.23 |
50.77 |
| 2021-06-30 |
103.57 |
$1.66 |
62.44 |
| 2021-03-31 |
83.64 |
$1.14 |
73.64 |
| 2020-12-31 |
91.23 |
$1.02 |
89.06 |
| 2020-09-30 |
79.82 |
$1.09 |
73.13 |
| 2020-06-30 |
69.11 |
$1.49 |
46.47 |
| 2020-03-31 |
62.87 |
$1.72 |
36.58 |
| 2019-12-31 |
77.76 |
$1.46 |
53.32 |
| 2019-09-30 |
73.30 |
$1.30 |
56.21 |
| 2019-06-30 |
61.58 |
$1.14 |
54.03 |
| 2019-03-31 |
63.78 |
$-0.28 |
0.00 |
| 2018-12-31 |
51.06 |
$0.27 |
188.54 |
| 2018-09-30 |
58.03 |
$0.32 |
182.38 |
| 2018-06-30 |
48.52 |
$0.13 |
369.28 |
| 2017-12-31 |
37.57 |
$1.29 |
29.23 |
| 2017-09-30 |
36.44 |
$1.44 |
25.24 |
| 2017-06-30 |
39.41 |
$1.20 |
32.90 |
| 2017-03-31 |
31.36 |
$1.22 |
25.67 |
| 2016-12-31 |
31.23 |
$1.28 |
24.33 |
| 2018-03-31 |
46.51 |
$0.76 |
60.86 |
| 2016-09-30 |
40.19 |
$0.70 |
57.74 |
| 2016-06-30 |
33.24 |
$0.72 |
45.94 |
| 2016-03-31 |
29.40 |
$0.72 |
40.92 |
| 2015-12-31 |
26.33 |
$0.68 |
38.92 |
| 2015-09-30 |
23.70 |
$0.67 |
35.32 |
| 2015-06-30 |
23.74 |
$0.38 |
62.24 |
| 2015-03-31 |
23.74 |
$1.34 |
17.78 |
| 2014-12-31 |
21.23 |
$1.45 |
14.66 |
| 2014-09-30 |
17.03 |
$1.49 |
11.44 |
| 2014-06-30 |
14.31 |
$1.68 |
8.54 |
| 2014-03-31 |
12.36 |
$0.64 |
19.45 |
| 2013-12-31 |
10.96 |
$0.54 |
20.45 |
| 2013-09-30 |
11.61 |
$0.50 |
23.03 |
| 2013-06-30 |
11.20 |
$0.49 |
22.89 |
| 2013-03-31 |
13.69 |
$0.52 |
26.25 |
| 2012-12-31 |
15.03 |
$0.36 |
41.65 |
| 2012-09-30 |
17.90 |
$0.35 |
50.77 |
| 2012-06-30 |
17.22 |
$0.34 |
50.34 |
| 2012-03-31 |
12.12 |
$-0.01 |
0.00 |
| 2011-12-31 |
11.78 |
$0.16 |
75.01 |
| 2011-09-30 |
11.88 |
$0.18 |
66.74 |
| 2011-06-30 |
14.53 |
$0.09 |
170.94 |
| 2010-12-31 |
13.47 |
$0.27 |
49.12 |
| 2010-09-30 |
11.18 |
$0.45 |
24.68 |
| 2010-06-30 |
9.34 |
$0.34 |
27.46 |
| 2010-03-31 |
8.24 |
$0.46 |
17.74 |
| 2009-12-31 |
7.24 |
$0.53 |
13.76 |
| 2011-03-31 |
14.50 |
$0.22 |
67.04 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$48.354B |
$5.233B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
